Optibrium Ltd, a UK software developer with artificial intelligence technology for drug discovery, has appointed Hamed Tabatabaei Ghomi as head of research. He will lead the application of machine learning and quantum mechanics to the discovery of new therapeutics in order to make the process more efficient. He joins Optibrium from Illumina Inc where he was bioinformatics manager. Dr Ghomi holds a PhD in the philosophy of science from the University of Cambridge, UK, and a PhD in computational drug design from Perdue University, US.
He started his career as a pharmacist at Exir Pharmaceutical Company in Iran.
Optibrium announced the appointment on 4 April 2023.
Copyright 2023 Evernow Publishing Ltd